
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
Shanghai HEP Pharma Co. has signed a new agreement with OmniComm Systems, Inc which will officially name them as TrialMaster's first customer in China. Under this agreement, Shanghai HEP Pharma will use OmniComm's TrialMaster EDC to conduct a hepatitis B study.
Read the full release






